Human herpesvirus 6 (HHV-6) and CMV reactivation were monitored in a cohort of 72 consecutive haematopoietic stem cell transplant (HSCT) patients using RQ-PCR and antigenaemia assay, respectively. The association between acute GVHD (aGVHD) and HHV-6B/ CMV was evaluated. We found that on day 100 the cumulative incidence of grades I-IV aGVHD, grades II-IV aGVHD and grades III-IV aGVHD was 55.6, 27.8 and 13.9%, respectively. Multivariate analysis indicated that HHV-6B reactivation was closely correlated with a higher probability of grade II-IV aGVHD by day 30 (Hazard ratio (HR), 8.9; 95% confidence interval (CI), 2.6-31.0; P ¼ 0.0006), by day 50 (HR, 6.1; 95% CI, 2.1-17.8; P ¼ 0.0010) and by day 100 (HR, 4.8; 95% CI, 1.7-13.6; P ¼ 0.0028). However, CMV reactivation did not significantly affect the development of aGVHD by day 50 (HR, 0.8; 95% CI, 0.1-6.7; P ¼ 0.8236) and by day 100 (HR, 0.5; 95% CI, 0.1-4.4; P ¼ 0.5330) after HSCT. In conclusion, this study demonstrated that active HHV-6B infection, but not CMV, is significantly associated with an increased risk of aGVHD development after HSCT.
Introduction
Despite the improvements in immunosuppressive therapy, GVHD still remains a major obstacle in allogeneic haematopoietic stem cell transplant (HSCT) patients. 1 CMV, a member of the b human herpesvirus subfamily, has been identified as the most important human herpesvirus correlated with acute GVHD (aGVHD) in HSCT recipients. 2, 3 Several studies have demonstrated that HHV-6 infection is correlated with the development of aGVHD or aGVHD-related skin rash, 4, 5 but controversies still exist. 6, 7 In this study, we monitored active HHV-6B and CMV infection in 72 consecutive allogeneic HSCT recipients using RQ-PCR and antigenaemia assay. Moreover, we evaluated the association of HHV-6B/CMV infection with aGVHD in allogeneic HSCT recipients.
Patients and methods

Eligibility of patients
Our study cohort consists of patients who underwent allogeneic HSCT between May 2004 and June 2005 at Peking University Institute of Haematology and Beijing Dao-Pei Hospital. Informed consent to participate was obtained from all patients. The protocol of this study was approved by the Institutional Review Board at Peking University Institute of Haematology. Blood samples were collected prospectively from each subject before transplantation and then weekly until 12 weeks after HSCT or discharge. The clinical data were analysed retrospectively. Altogether, 72 patients were enrolled in our study. A total of 680 EDTA-anticoagulated peripheral blood samples were obtained.
HSCT characteristics
Clinical characteristics of the 72 patients are listed in Table 1 . Forty-seven patients with matched sibling donors were conditioned with Bu/Cy2 or Cy/TBI, whereas 25 patients with matched unrelated or mismatched related donors HSCT were conditioned with Bu/Cy2 plus antithymocyte globulin (ATG, IMTIX, France). 8 Prophylaxis for aGVHD consisted of both CSA and mycophenolate mofetil and a short course of methotrexate for all patients. The first-line therapeutic reagent for aGVHD was intravenous methylprednisolone. Tacrolimus and reinstitution of mycophenolate mofetil were the second-line therapy for established aGVHD. Prophylaxis of herpesvirus infection consisted of i.v. ganciclovir (GCV) 5 mg/kg every 12 h from days À9 to À2 pretransplantation, and oral acyclovir 400 mg twice daily during the first month after HSCT.
Preemptive therapy with either GCV or foscarnet was instituted after CMV antigenaemia was confirmed.
RQ-PCR and HHV-6 variants determination DNA was extracted from PBMCs using a whole-blood genome DNA extraction kit according to the manufacturer's instructions (Tiangen, Beijing, China). An RQ-PCR assay for the detection of HHV-6 DNAemia in PBMNCs was performed with an ABI 7500 RQ-PCR System (Applied Biosystems, Foster City, CA, USA). The primers and probes for amplification of HHV-6 viral sequences and the sequences of an internal reference gene-human recombination activating gene 1 have been described previously.
9,10 The RQ-PCR was performed in a final volume of 25 ml containing TaqMan Universal PCR Master Mix (Applied Biosystems), 830 nM each of primer, 100 nM of TaqMan probe and 100 ng of DNA template. The TaqMan PCR cycling conditions were as follows. After 2 min at 50 1C and 10 min at 95 1C, samples were submitted to 40 cycles, each comprising 15 s at 95 1C and 60 s at 62 1C. A standard curve of HHV-6 PCR assay was generated with serially 10-fold-diluted plasmids (10 2 -10 7 copies), containing HHV-6 target fragment (kindly donated by Dr Zerr, University of Washington). The HHV-6 DNA copies in the PBMCs were determined by comparing the data with the standard curve and expressed as the number of HHV-6-equivalent genome copies per 10 6 PBMCs (copies/ 10 6 PBMCs). The sensitivity of RQ-PCR assays for HHV-6 was 10 copies determined using the serial dilution of plasmid standards (10 0 -10 7 copies). All standards and samples were assayed in duplicate. A positive control and a negative control (no template added) were included in each assay.
Human herpesvirus 6 subtypes were determined by HindIII cleavage of nested PCR products. A nested PCR was performed to amplify a U31 gene fragment for both HHV-6 variants A and B. Details of nested PCR have been described previously. 11 The PCR amplicon for HHV-6 variant B was cleaved by HindIII to 370-bp and 122-bp fragments, whereas the variant A amplicon remained uncut.
CMV antigenaemia assay
Ethylene-diaminetetraacetic acid-anticoagulated peripheral blood samples were obtained weekly after transplantation for detection of CMV pp65 antigenaemia. PBMNCs were isolated by Ficoll-Hypaque density gradient centrifugation and cytocentrifuged onto microscope slides. CMV antigenaemia assay was carried out using a CMV Brite TM kit (IQ Corporation, Groningen, Holland) according to the manufacturer's instructions.
Definitions
Acute GVHD was defined and graded by previously published criteria.
12,13 CMV reactivation was defined as X1 positive cell per 10 5 PBMCs detected by CMV pp65 antigenaemia assay.
14 HHV-6 reactivation was defined as the detection of 10 copies of viral DNA/10 6 PBMCs by RQ-PCR.
Statistical analysis
To evaluate the effect of HHV-6B and/or CMV on grades II-IV aGVHD, we used a Cox regression model by censoring cases at 30, 50 and 100 days, respectively. HHV-6B and CMV were treated as a time-dependent covariate, that is, a patient was considered as having HHV-6B reactivation or CMV antigenaemia only if this study time passes his/her onset time of HHV-6B or CMV, respectively. All reported P-values were two-sided. Po0.05 was considered as statistically significant.
A multistate model was used to describe the complicated association between HHV-6B/CMV and grades II-IV aGVHD after HSCT, and to compute the cumulative incidence probability (CIP) of developing aGVHD by HHV-6B and by CMV, respectively. All patients were alive without HHV-6B/CMV or grades II-IV aGVHD after HSCT (State 0). Patients can die before developing aGVHD and HHV-6B/CMV (State 1) or developing aGVHD without having HHV-6B/CMV (State 2) or having HHV-6B/CMV without developing aGVHD (State 3). Patients who entered state 3 can die without developing aGVHD (State 4) or developing aGVHD (State 5). The cumulative incidence probability of developing aGVHD at a given time point is the probability of a patient entering in state 2 or in state 5 before the given time point, which can be separated by the cumulative incidence probability of aGVHD without having HHV-6B/CMV (state 2) and the HHV-6B and CMV with aGVHD L-R Wang et al cumulative incidence probability of aGVHD after having HHV-6B/CMV (state 5).
Results
Incidence of active HHV-6 and CMV infection
Neither HHV-6A nor HHV-6B DNA could be detected in samples obtained before HSCT. HHV-6A DNA was detected in only one patient (1.4%) at days 14, 21 and 28 after HSCT. The details of HHV-6A infection were described previously. 11 HHV-6B DNA, identified as the predominant variant in our subjects, was detected at least once in 47.2% (34/72) of the recipients on the median of day 21 (range, 7-84 days) after HSCT. Most of the HHV-6B infections occurred between the second and the seventh week after HSCT, with the peak incidence in the fourth week (27.1%). The peak of HHV-6B DNA load was reached in the third week when the median level of DNA loads was as high as 2562 copies/10 6 PBMCs (range, o10-27 950 copies/10 6 PBMNCs). CMV pp65 antigen was detected at least once in 65.3% (47/72) of the recipients on the median of day 43 (range, 14-100 days) after HSCT.
Acute GVHD Of the 72 subjects, the incidence of grades I-IV aGVHD was 55.6% (40/72) and the median onset time was 26 days (range, 9-73 days); for grades III-IV, the incidence was 27.8% (20/72) and the median onset time was 22 days (range, 9-59 days); and for grades III-IV, the incidence was 13.9% (10/72) and the median onset time was 25 days (range, 10-49 days).
The association between HHV-6B/CMV reactivation and grades II-IV aGVHD Cox regression analysis. A Cox regression model treating HHV-6B/CMV as a time-dependent covariate was used to evaluate the HHV-6B/CMV effect on grades II-IV aGVHD. Patients with HHV-6B reactivation had a higher probability of subsequently developing grades II-IV aGVHD by day 30 (HR ¼ 8.9; 95% confidence interval (CI) ¼ 2.6-31.0; P ¼ 0.0006), by day 50 (HR ¼ 6.1; 95% CI ¼ 2.1-17.8; P ¼ 0.0010) and by day 100 (HR ¼ 4.8; 95% CI ¼ 1.7-13.6; P ¼ 0.0028) ( Table 2 ) after HSCT. To explore the association between HHV-6B viral loads and grades II-IV aGVHD, patients were classified into low (o100copies/10 6 PBMCs), intermediate (100-5000 copies/ 10 6 PBMCs) and high (45000copies/10 6 PBMCs) viral level groups on the basis of HHV-6 DNA load. The cumulative incidences of grades II-IV aGVHD in low, intermediate and high viral level groups were 13.8, 47.1 and 54.6%, respectively. Compared with patients with low viral level of HHV-6B, the patients with intermediate and high viral level of HHV-6B had increased probability of subsequent development of grades II-IV aGVHD (P ¼ 0.0005).
Patients with CMV antigenaemia had no effect on the occurrence of grades II-IV aGVHD by day 50 (HR ¼ 0.8; 95%CI ¼ 0.1-6.7; P ¼ 0.8200) and by day 100 (HR ¼ 0.5; 95% CI ¼ 0.1-4.4; P ¼ 0.5300) ( Table 2) .
Multistate model analysis. For HHV-6B, 27 patients were alive without aGVHD and HHV-6B reactivation (stay in state 0) at the end of study (day 100 after HSCT); 6 patients were dead without aGVHD and HHV-6B reactivation (state 1); 11 patients developed aGVHD without HHV-6B reactivation (state 2) (among these patients, 6 eventually developed HHV-6B after aGVHD); 28 patients entered state 3 (developed HHV-6B DNAemia without aGVHD; among these patients, 19 stayed in state 3 at day 100 after HSCT; 9 patients then developed aGVHD after HHV-6B reactivation (state 5)). Figure 1 plots the CIP of aGVHD by HHV-6B: curve (1) was the CIP of aGVHD without HHV-6B reactivation. Curve (2) is the CIP of overall aGVHD. Curve (2) À curve (1) is the CIP of aGVHD after HHV-6B reactivation. At day 100 after HSCT, the CIP of aGVHD after having HHV-6B reactivation is 0.1250 (s.e. ¼ 0.0386), with a Po0.0001 of testing CIP ¼ 0, which indicated that HHV-6B had a significant effect on developing aGVHD.
For CMV antigenaemia, 20 patients were alive without aGVHD and CMV antigenaemia (stay in state 0) at the end of study (day 100 after HSCT); 3 patients dead without aGVHD and CMV antigenaemia (state 1); 19 patients Table 2 The effect of HHV-6B/CMV reactivation on grades II-IV aGVHD analysed by Cox regression
Covariate
Grades II-IV aGVHD (2) minus (1) equals to probability of aGVHD following HHV-6B reactivation
Cumulative incidence probability (CIP) of grade II-IV aGVHD by HHV-6B Cumulative incidence Figure 1 Cumulative incidence probability of developing grades II-IV acute GVHD with or without human herpesvirus-6, variant B reactivation.
HHV-6B and CMV with aGVHD L-R Wang et al developed aGVHD without CMV reactivation (state 2) (among them, 17 patients eventually developed CMV antigenaemia after aGVHD); 30 patients entered state 3 (had CMV antigenaemia without aGVHD; among them, 26 patients stayed in state 3 at day 100 after HSCT; 3 patients were dead without aGVHD after CMV reactivation (state 4)); 1 patient then developed aGVHD after CMV antigenaemia (state 5). The CIP plot of aGVHD by CMV was given in Figure 2 , where curve (1) was the CIP of aGVHD without CMV reactivation, curve (2) was the CIP of overall aGVHD, curve (2) À curve (1) was the CIP of aGVHD after CMV antigenaemia. At day 100 after HSCT, the CIP of aGVHD after having CMV antigenaemia was 0.0139 (s.e. ¼ 0.0140) with a P ¼ 0.3190 of testing CIP ¼ 0, which indicated that CMV antigenaemia had no effect on aGVHD.
Discussion
Our study indicated that both HHV-6B and CMV reactivation were frequent in post-HSCT recipients. Moreover, HHV-6B, but not CMV, reactivation was significantly correlated with the occurrence of grades II-IV aGVHD. The analyses of the association between HHV-6B reactivation and other post-transplant complications except aGHVD had been published by the authors elsewhere. 11, 15 In recent years, much attention has been paid to the pathogenic effect of herpesvirus on the development of aGVHD, but the specific contribution of HHV-6 to the occurrence of aGVHD in HSCT recipients has thus far not been definitely clarified. Yoshikawa et al. 16, 17 reported that HHV-6 DNA can be isolated from skin samples of patients with early skin rash. Tomonari et al. 5 reported that high HHV-6 DNA levels in the third week after cord blood transplantation correlated with the development of grades II-IV aGVHD In this study, our results provide clear evidence that active HHV-6B infection is significantly associated with the development of aGVHD in allogeneic HSCT recipients, because patients with early HHV-6B reactivation have an increased probability of developing aGVHD. On the other hand, although CMV infection has been reported to be associated with aGVHD, 2, 3 there was no significant impact of CMV reactivation on the occurrence of grades II-IV aGVHD in our study. At this point, the effect of GCV treatment should be taken into account. In our patients, GCV treatment was started promptly when CMV antigenaemia was identified, whereas it was not started when HHV-6 infection was verified. We carefully analysed the data and found that co-infections of HHV-6 and CMV occurred in 11 patients. In all 11 patients, the HHV-6 DNAemia had become detectable before CMV antigenemia was verified. GCV can induce CMV antigenaemia clearance and HHV-6 DNA copy number reduction in patients who receive GCV therapy by reason of CMV infection. Thus, it is possible that GCV affected HHV6B levels less than CMV levels because treatment was delayed. The underlying mechanism of the effect of HHV-6 infection on the occurrence of aGVHD remains unknown. There are at least three possibilities. First, herpesviruses may augment the graft-versus-host reaction by directly or indirectly modifying the regulation of the host immune response. HHV-6 can directly damage HHV-6-infected CD4 þ T cells. 18 Infection with HHV-6 results in suppression of T-lymphocyte function, as evidenced by reduced IL-2 synthesis and cellular proliferation. 19 The direct and indirect effect of HHV-6 infection on the host immune system may result in a failure, or at least a decrease, in the ability of the host cells to 'fight back' against donor T effector cells. Second, HHV-6 may stimulate T cytotoxic cells against the host cells by upregulating the expression of HLA class I and class II molecules, and this may result in more efficient activation of class II-reactive donor T helper cells, thus lowering the threshold for the induction of aGVHR. 17, 20 Third, HHV-6 may increase the expression of key molecules involved in the development of GVHD, such as intercellular adhesion molecule-1, vascular adhesion molecule-1, 21 IL-1, tumour necrosis factor-a 22 and the CC chemokine RANTES. 23 In short, HHV-6 might take part in the evolution or development of aGVHD through the direct effect of infiltrating T lymphocytes and by modulating key molecules and chemokines. A better understanding of the association between HHV-6 infection and aGVHD may lead clinicians to adopt a more positive strategy to monitor and treat herpesvirus infection in patients after HSCT.
In conclusion, our data provide evidence that HHV-6 infection, but not CMV infection, significantly increases the incidence of aGVHD after HSCT. Therefore, surveillance of HHV-6 reactivation in the early period post-HSCT and the preemptive use of anti-viral therapy may reduce the incidence of aGVHD. (2) minus (1) equals to probability of aGVHD following CMV Cumulative incidence probability (CIP) of grade II-IV aGVHD by CMV Cumulative incidence Figure 2 Cumulative incidence probability of developing grades II-IV acute GVHD with or without CMV reactivation. manuscript and Tong Wu for carefully reading the manuscript.
